Literature DB >> 29695572

The Feasibility and Efficacy of Laparoscopic Extended Total Mesorectal Excision for Locally Advanced Lower Rectal Cancer.

Takashi Nonaka1, Akiko Fukuda2, Kyoichiro Maekawa2, Shigeki Nagayoshi2, Takayuki Tokunaga2, Mitsutoshi Takatsuki2, Tomoo Kitajima2, Ken Taniguchi2, Hikaru Fujioka2.   

Abstract

BACKGROUND/AIM: Extended total mesorectal excision (ETME) is defined as en bloc resection of the adjacent organs outside the mesorectal fascia, that is indicated in cases with locally advanced lower rectal cancer (T4 tumor). The aim of this study was to evaluate the clinical and oncological outcomes of laparoscopic ETME (L-ETME) for locally advanced lower rectal cancer. PATIENTS AND METHODS: The present study analyzed clinical outcomes and oncological outcomes of 11 consecutive patients who underwent L-ETME for cT4 lower rectal cancer in Nagasaki Medical Center between 2012 and 2015.
RESULTS: Of the 11 patients, 7 underwent neoadjuvant therapy, and 7 underwent pelvic node dissection. One case (7.1%) underwent resection of anterior organs (prostate), 6 cases (54.5%) had resection of the lateral organs (neurovascular bundle, hypogastric nerve, pelvic plexus, ovary, and internal iliac blood vessels) and 4 cases (36.4%) had resection of both anterior and lateral organs. In all cases enrolled in this study, R0 resection was achieved. The median operation time and intraoperative blood loss were 416 min and 350 ml, respectively. The postoperative complication rate was 18.2% (2/11). The 3-year overall survival rate was 79.5%, and the 3-year local recurrence-free survival rate was 87.5%. There was no mortality and no re-operation in this series.
CONCLUSION: The results of the present study suggest that L-ETME is feasible and has efficacy for locally advanced lower rectal cancer. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Locally advanced lower rectal cancer; extended TME; laparoscopic surgery

Mesh:

Year:  2018        PMID: 29695572      PMCID: PMC6000797          DOI: 10.21873/invivo.11287

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer.

Authors:  D G Jayne; H C Thorpe; J Copeland; P Quirke; J M Brown; P J Guillou
Journal:  Br J Surg       Date:  2010-11       Impact factor: 6.939

2.  Laparoscopic abdominosacral resection for locally advanced primary rectal cancer after treatment with mFOLFOX6 plus bevacizumab, followed by preoperative chemoradiotherapy.

Authors:  Toshiya Nagasaki; Takashi Akiyoshi; Masashi Ueno; Yosuke Fukunaga; Satoshi Nagayama; Yoshiya Fujimoto; Tsuyoshi Konishi; Toshiharu Yamaguchi
Journal:  Asian J Endosc Surg       Date:  2014-01

3.  Long-term oncologic outcomes of laparoscopic vs open surgery for stages II and III rectal cancer: A retrospective cohort study.

Authors:  Zhen-Xu Zhou; Li-Ying Zhao; Tian Lin; Hao Liu; Hai-Jun Deng; Heng-Liang Zhu; Jun Yan; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

4.  Minimally invasive colon resection (laparoscopic colectomy).

Authors:  M Jacobs; J C Verdeja; H S Goldstein
Journal:  Surg Laparosc Endosc       Date:  1991-09

5.  Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial.

Authors:  Sung-Bum Kang; Ji Won Park; Seung-Yong Jeong; Byung Ho Nam; Hyo Seong Choi; Duck-Woo Kim; Seok-Byung Lim; Taek-Gu Lee; Dae Yong Kim; Jae-Sung Kim; Hee Jin Chang; Hye-Seung Lee; Sun Young Kim; Kyung Hae Jung; Yong Sang Hong; Jee Hyun Kim; Dae Kyung Sohn; Dae-Hyun Kim; Jae Hwan Oh
Journal:  Lancet Oncol       Date:  2010-06-16       Impact factor: 41.316

6.  Laparoscopic extended lateral pelvic node dissection following total mesorectal excision for advanced rectal cancer: initial clinical experience.

Authors:  Jun Seok Park; Gyu-Seog Choi; Kyoung Hoon Lim; You Seok Jang; Hye Jin Kim; Soo Yeon Park; Soo Han Jun
Journal:  Surg Endosc       Date:  2011-05-10       Impact factor: 4.584

7.  Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging.

Authors:  S G Larsen; J N Wiig; H L Emblemsvaag; K K Grøholt; K H Hole; A Bentsen; S Dueland; T Vetrhus; K-E Giercksky
Journal:  Colorectal Dis       Date:  2008-07-25       Impact factor: 3.788

8.  Short-term outcomes from a prospective randomized trial comparing laparoscopic and open surgery for colorectal cancer.

Authors:  J Neudecker; F Klein; R Bittner; T Carus; A Stroux; W Schwenk
Journal:  Br J Surg       Date:  2009-12       Impact factor: 6.939

9.  Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period.

Authors:  Seiji Ishiguro; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Miranda Kusters; Yoshihiro Moriya
Journal:  Surgery       Date:  2008-12-23       Impact factor: 3.982

10.  Lateral pelvic lymph node dissection for advanced lower rectal cancer.

Authors:  S Fujita; S Yamamoto; T Akasu; Y Moriya
Journal:  Br J Surg       Date:  2003-12       Impact factor: 6.939

View more
  1 in total

1.  Extended Lymphadenectomy in Locally Advanced Rectal Cancers: A Systematic Review.

Authors:  Balaji Mahendran; Supriya Balasubramanya; Simone Sebastiani; Sebastian Smolarek
Journal:  Ann Coloproctol       Date:  2021-11-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.